Anlon Healthcare Stock Price Today (NSE: AHCL)
Fundamental Score
Anlon Healthcare Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Anlon Healthcare share price today is ₹13.63, up +0.29% on NSE/BSE as of 19 June 2026. Anlon Healthcare (AHCL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹879.52 (Cr). The 52-week high for AHCL share price is ₹172.75 and the 52-week low is ₹11.22. At a P/E ratio of 32.28x, AHCL is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 40.45% and a debt-to-equity ratio of 0.27.
Anlon Healthcare Share Price Chart — NSE/BSE Historical Performance
Anlon Healthcare share price chart: -1.93% return over the past month. 52-week high ₹172.75, 52-week low ₹11.22.
Anlon Healthcare — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹13.45 | ₹13.96 | ₹13.45 | ₹13.63 | 16.76L (Cr) | |
| ₹13.98 | ₹13.98 | ₹13.50 | ₹13.59 | 10.40L (Cr) | |
| ₹14.29 | ₹15.02 | ₹13.52 | ₹13.85 | 100.72L (Cr) | |
| ₹14.25 | ₹14.25 | ₹14.25 | ₹14.25 | 0.00 (Cr) | |
| ₹14.18 | ₹14.35 | ₹14.00 | ₹14.25 | 15.41L (Cr) | |
| ₹13.77 | ₹14.52 | ₹13.73 | ₹14.05 | 31.43L (Cr) | |
| ₹13.99 | ₹14.19 | ₹13.70 | ₹13.78 | 8.69L (Cr) | |
| ₹14.05 | ₹14.24 | ₹13.68 | ₹13.91 | 9.51L (Cr) | |
| ₹13.44 | ₹14.40 | ₹13.35 | ₹13.89 | 41.73L (Cr) | |
| ₹13.40 | ₹13.60 | ₹13.26 | ₹13.31 | 9.08L (Cr) |
Anlon Healthcare — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹13.98 | ₹13.98 | ₹13.45 | ₹13.63 | -2.50% | |
| ₹13.50 | ₹15.02 | ₹12.99 | ₹13.85 | +2.59% | |
| ₹114.94 | ₹117.70 | ₹11.22 | ₹13.30 | -88.43% | |
| ₹106.69 | ₹133.00 | ₹103.71 | ₹111.38 | +4.40% | |
| ₹121.00 | ₹132.00 | ₹106.29 | ₹108.52 | -10.31% | |
| ₹151.80 | ₹161.00 | ₹121.50 | ₹122.40 | -19.37% | |
| ₹169.96 | ₹172.40 | ₹133.01 | ₹150.95 | -11.18% | |
| ₹128.00 | ₹172.75 | ₹128.00 | ₹168.61 | +31.73% | |
| ₹133.50 | ₹134.50 | ₹119.15 | ₹128.61 | -3.66% | |
| ₹92.00 | ₹147.70 | ₹90.78 | ₹131.16 | +42.57% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Anlon's inorganic growth strategy is a high-risk, high-reward bet on its ability to transform from an API manufacturer into a diversified pharma player.
WHAT'S HAPPENING NOW
Anlon Healthcare approved the acquisition of 63.98% stake in Remember India Health Links for on April 16, 2026. This acquisition aims to transform Anlon from an API manufacturer to a complete pharmaceutical provider. The company also completed the acquisition of 56.67% equity shareholding in Bizotic Life Science on March 20, 2026. A stock split (1:5) and bonus issue (1:1) are scheduled, with a record date of April 24, 2026. Brickwork Ratings withdrew credit ratings for Anlon's bank loan facilities worth and term loans of
CORE STORY
Anlon is aggressively pivoting from a pure-play API manufacturer to a diversified pharmaceutical company with finished dosage capabilities. It's an inorganic growth story, buying its way into the next stage of the value chain.
- Acquisition of Remember India Health Links approved on April 16, 2026
- Stock split and bonus issue with record date April 24, 2026
- Completion of Bizotic Life Science acquisition on March 20, 2026
- Successful integration of Remember India Health Links
- Strong Q1 2027 earnings showcasing benefits of acquisitions
- New order wins for finished dosage formulations
- Small-cap liquidity risk
- Integration risk from acquisitions
- Declining turnover of Remember India Health Links in FY25
Promoter holding stable at 52.68%. No change in FII/DII holdings.
Indian pharma sector benefiting from government initiatives like Biopharma SHAKTI and a push for domestic manufacturing.
₹5.38 crore acquisition of Remember India Health Links approved on April 16, 2026.
Negative free cash flow of ₹-47.27 Cr over the last 5 years raises concerns.
Anlon's future hinges on successful integration of acquired businesses and a shift towards higher-margin finished dosage formulations. Expect volatility as the market assesses the execution of this strategy.
Primary Thesis Risk
Failed integration of acquisitions will derail Anlon's transformation and expose its stretched valuation.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Anlon Healthcare Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Anlon Healthcare Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AHCL across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (40.45%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (24.83%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (16.42%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (259.85%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (115.97%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Conservative Debt Levels (D/E: 0.27)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (7.64x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (52.68%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Negative Free Cash Flow (₹-47.27 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 2.83%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Anlon Healthcare vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Anlon Healthcare with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Anlon HealthcareAnlon Healthcar...Selected✓ AHCL • 544497 | 49/100 | ₹13.63₹14 | ₹879.52₹879.52 | 32.28Average 32.3 Average | 40.45%Excellent 40.45% Excellent | 24.83%Excellent 24.83% Excellent | 0.27Excellent 0.3 Excellent | — — | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1796.50₹1797 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6553.50₹6554 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4350.40₹4350 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1390.30₹1390 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1290.40₹1290 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2262.90₹2263 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1091.20₹1091 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2320.20₹2320 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1433.70₹1434 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5314.50₹5315 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Anlon Healthcare Quarterly Performance
Latest quarterly metrics for AHCL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
115.97%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
259.85%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Anlon Healthcare Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AHCL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Anlon Healthcare Financial Statements
Annual income statement, balance sheet and cash flow for Anlon Healthcare (AHCL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Anlon Healthcare
About AHCL (Anlon Healthcare)
Anlon Healthcare is a multifaceted pharmaceutical entity, dedicated to the synthesis and distribution of sophisticated pharmaceutical components across the globe. The company speci...alizes in crafting meticulously engineered intermediates, the crucial building blocks that underpin the creation of final drug formulations. These components are designed to meet the rigorous demands of modern pharmaceutical manufacturing, ensuring both efficacy and safety in the end products. Anlon Healthcare operates with a commitment to precision and innovation, constantly seeking to improve its processes and product offerings to stay at the forefront of the ever-evolving pharmaceutical landscape. Their commitment to quality extends to all stages of their operations, from research and development to manufacturing and distribution. The company's expansive portfolio encompasses a wide array of specialized pharmaceutical ingredients, catering to diverse therapeutic areas. Anlon Healthcare produces active pharmaceutical ingredients (APIs), the very core of medicinal action, as well as nutraceutical APIs for health and wellness applications. They also develop ingredients tailored for personal care products, contributing to advancements in skincare and cosmetic formulations. Further extending their reach, Anlon Healthcare provides veterinary APIs, ensuring the health and well-being of animals. This diversity reflects the company's ability to adapt and innovate, meeting the varying needs of both human and animal healthcare sectors with tailored solutions. By serving various sectors, Anlon is contributing to innovation of healthcare. Anlon Healthcare's products serve as essential components in numerous therapeutic categories, contributing to advancements in treatment and management. These include drugs used in addressing inflammation, pain relief, and fever reduction, as well as antihistamines, antidepressants, and antipsychotics for mental health applications. Their ingredients are also vital in the production of anticoagulants, antihypertensives, and medications for managing conditions such as arrhythmia, hyperparathyroidism, and diabetes. By consistently producing high-quality intermediates and APIs, Anlon Healthcare contributes to the continuous development of novel therapeutic solutions and the improvement of patient outcomes globally. By focusing on innovation, Anlon is constantly adapting to the change in pharmaceutical needs.
Company Details
Key Leadership
Latest News
AHCL Share Price: Frequently Asked Questions
What is the current share price of Anlon Healthcare?
Anlon Healthcare (AHCL) trades at ₹13.63 on NSE and BSE. Market cap ₹879.52 (Cr). Educational data only.
What is the P/E ratio of Anlon Healthcare?
Anlon Healthcare has a P/E of 32.28x vs industry average 31.77x.
What is the Bull Run score for Anlon Healthcare?
Anlon Healthcare has a Bull Run score of 49/100 based on 25+ financial parameters.
Does Anlon Healthcare pay dividends?
Anlon Healthcare has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Anlon Healthcare?
Anlon Healthcare has ROE of 40.45%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Anlon Healthcare?
Anlon Healthcare has debt-to-equity of 0.27.
Is Anlon Healthcare a good investment?
Bull Run gives Anlon Healthcare a score of 49/100. This is not investment advice — consult a SEBI-registered advisor.